Posted on Authorea 16 Sep 2020 — The copyright holder is the author/funder. All rights reserved. No reuse without permission. — https://doi.org/10.22541/au.160029792.26609294 — This a preprint and has not been peer reviewed. Data may be preliminary. namto lsl novdi h ahgnsso 2Madteporsino eae complications re- related of insulin progression to the due and hyperglycemia T2DM of by pathogenesis recognized the diseases in involved metabolic secretion closely a inflammation insulin is insufficient (T2DM) and mellitus sistance diabetes 2 Type circulating improving miR-146a. for of beneficial Introduction regulation its be down might or and supplementation astaxanthin IL-6 astaxanthin and of that MDA with effect suggests patients study the in present evaluate inflammation The and to stress designed oxidative mellitus. miR-126, was diabetes and that 2 miR-146a investigation type of human expression the first on the constituents mellitus. is diabetes study 2 This type with patients expression in the inflammation on new constituents and What its stress or oxidative astaxanthin of miR-126, effect and the investigate miR-146a to astaxanthin. of studies of human effects no been antinflamatory have and There antioxidant the showed studies previous Some results. these confirm to known? suggested are What’s investigations future However, miR-146a. of regulation Astaxanthin down that and observed IL-6 We and Results: (P MDA (P IL-6 weeks. -1/388) and 8 MDA change: for (Fold randomly of placebo(n=22) time were levels or who plasma patients (n=22) decrease diabetes Astaxanthin/d Astaxanthin could 2 oral patients of supplementation type Methods: of effects hyperglycemic 44 8mg diabetes. on the and received 2 conducted determinate type to was diabetic is with to trial assigned patients It in in clinical was inflammation placebo-controlled regulate study and inflammation. double-blind MDA this up- randomized miR-126, and of This and miRNA-146a stress miR-146a purpose as of oxidative expression the such chronic the Therefore, on miRNAs with supplementation reduces. some associated miRNA-126 of is circulating expression (T2D) whereas, the diabetes that 2 known type well of pathogenesis The Background: Abstract 2020 16, September 3 2 1 Mohammadi-asl farokhzad Amirhossein blind double randomized trial A clinical controlled mellitus: placebo diabetes 2 in type inflammation with and patients stress of oxidative expression miR-126, the and on miR-146a supplementation astaxanthin of effects The ha odsaorUiest fMdclSciences Medical of University Jondishapour Sciences Ahvaz Medical of University Isfahan available not Affiliation 3 eros Zakerkish Mehrnoosh , < 1 ashSkiMashhadi Sokri Nafiseh , .5.Cnlso:Atxnhnsplmnainmgtb eeca o mrvn circulating improving for beneficial be might supplementation Astaxanthin Conclusion: 0.05). 1 rwn vdneidctdta hoi xdtv tesand stress oxidative chronic that indicated evidence Growing . 3 n ai Mohammadshahi Majid and , 1 2 < aymTahmasebi Maryam , .5 n elndteepeso ee fmR16 over miR-146a of level expression the declined and 0.05) 3 3 Javad , 2,3 . Posted on Authorea 16 Sep 2020 — The copyright holder is the author/funder. All rights reserved. No reuse without permission. — https://doi.org/10.22541/au.160029792.26609294 — This a preprint and has not been peer reviewed. Data may be preliminary. h ape a esrda 3n sn LS lt edr lpopoi cd(% n lTBA ml 1 and (1%) acid phosphoric of ml absorbance 3 The reader. complex. plate colored (TBA) ELISA red acid using a thiobarbituric 532nm produce with at to reacts measured (TBARS) MDA was were substance The samples reactive Samples protocol. the acid assay thiobarbituric TBRAS measurements. a using as biochemical peroxidation lipid for of state -80 index at the fasting stored by the and described frozen method in were collected serums and were centrifuged samples their blood preserve Venous to Measures them Primary asking and and Sampling tablets, to Blood AST ingestion. compliance residual medication participants’ the the and the intake, numeration lifestyle, appointment, macronutrient by diet, 2-week Hearst assessed and habitual each The was energy Division, During protocol Databank assess USA). study First To CA, 4.1, the Bruno, (Version food. software food San of IV (3-day and Nutritionist type period Corporation, using study and analyzed the weight were after data or and dietary both volume during Dioxide, for to before, Silicon used according recorded Acid, was were records), Stearic consumption which Cellulose, Food ingredients which Microcrytalline Stearate. USA) Phosphate, inactive Magnesium vision; Dicalcium and were (nature ( (microalgae) Astaxanthin/d placebo oral lowering subjects pluvialis and of supplement glucose Haematococcus for 8mg par- received from blood before the were subjects derived take presented characteristics fashion, was which and double-blinded Basal is during a activity, measurements. which In step, physical and interviewers weeks. collection each perform the data at diet, the by nutritionist all exact collected a performed an researchers of eat Qualified consent supervision to drugs. written the counseled The under vitamin were drinking. performed no ticipants project. and were the disease, smoking to processes inflammatory no joining All and other and before diseases and months, individual specific each thyroid 6 self-reported from no last obtained no of the disease, was lactation, diagnosis during heart definitive and supplement no pregnancy subjects, antioxidant old failure, no and therapy, years kidney insulin 30-60 no University including no Ahvaz malignancies, the criteria with at inclusion diabetes Center our Research II Diabetes met type diabetes the and to 2 Sciences referred type individuals Medical with These of volunteers study. Forty-four this manner, to trial joined placebo-controlled were randomized double-blind, the In design Study AST and of Population effects the Methods determinate and to Materials aimed and diabetes was inflammation of miR study reducing diabetes. prevention of this and 2 expression miRNAs, type and Therefore, circulating the treatment patients. on fish on the AST diabetes supplementation and in of in algae efficacy on stress in lipid the oxidative Astaxanthin pigment assessed controlling of studies common in few antioxidants and effect However, antioxidant family food xanthophyll of the the role demonstrated microRNAs to potential of modulating the belongs increase and in carotenoid an inflammation interest and diabetes-induced significant T2D release peroxidation, been to related insulin has stages there of disease Recently, different decline at the circulation the through in indicated evaluated is reduced pathogenesis are pancreatic T2D miRNA-126 in circulating whereas, MicroRNAs patients eventually is hyperglycemic II which and genes polymerase the RNA of 3’UTR by by degradation circulation transcribed interaction RNA their usually through to are level lead which expression gene RNA the noncoding modulate They small are (miRNAs) progression MicroRNAs its predicts and manifestations T2D precedes affect can inflammation Systemic β 7 rvossuisdtce h prglto fsm iNssc smRA16 ndiabetic in miRNA-146a as such miRNAs some of regulation up the detected studies Previous . cl apoptosis -cell Boster 6 10 h iNsepeso stsu-pcfi,btte a eosre nthe in observed be may they but tissue-specific, is expression miRNAs The . o rmaciia esetv,telvl fmR2aadmR16 a be can miR-146a and miR-26a of levels the perspective, clinical a from So, . ua L6EIAkt aodadhd MA ee a esrda an as measured was level (MDA) Malondialdehyde kit. ELISA IL-6 human β cl ucinlt n rmt iohnra yfnto htrslsin results that dysfunction mitochondrial promote and functionality -cell -146a n miR and 2 ° .Tesrmlvlo L6wsdtrie sn the using determined was IL-6 of level serum The C. 4 . -126 D n namto nptet with patients in inflammation and MDA , 11 n . 2 rpaeo( placebo or 22) = 8,9 12,13 nadto,priiaigof participating addition, In . saati AT sa is (AST) Astaxanthin . 14 eetstudies Recent . n 2 o 8 for 22) = 15 5 . . Posted on Authorea 16 Sep 2020 — The copyright holder is the author/funder. All rights reserved. No reuse without permission. — https://doi.org/10.22541/au.160029792.26609294 — This a preprint and has not been peer reviewed. Data may be preliminary. h etsucso aua S r la,yat idsceeslo,tot rl,adsrm n these ( of intervention and intake the shrimp and through limited, study and activity were the krill, physical AST during of participants’ trout, groups sources the salmon, the food in between Thus, sockeye detected differ participants. wild were not our yeast, of did Moreover, data algae, diet carotenoids obtained intervention. daily are other The the the AST in during intervention. included natural change the not of significantly were after not sources and intake did before best micronutrient parameters mellitus the and dietary diabetes carbohydrate, mentioned 2 protein, that type fat, showed energy, with dietary participants total the for among analyzed were records oral Dietary and groups. diabetes drugs, placebo activity antidepressant (BMI), or Physical oral index ASX and fat, mass 8mg Dietary body two body visceral weeks’ the the fat, between 8 gender, body drugs age, total the lowering medical (BMR), including glucose completed rate and characteristics them physical metabolic basic of basal baseline of duration, in 43 The terms in detailed study. study; observed of are this was none-compliance in subjects were enrolled of study were the characterization diabetes from Exclusion 2 type intervention. population with study subjects the Forty-four of characteristics anthropometric P and at Clinical set analyses was statistical significance All and 2- IL), comparison. Chicago, using pairwise Inc., evaluated post-test SPSS Results were Dunn’s 20, (Version miRNAs or SPSS, Turkey the using a was of performed with were matrix expression performed covariance relative was the test of Wallis Levels of statistics. homogeneity M and ΔΔ Box’s normality skewed performed (positively for pretest and using variables was tested studied groups the examined were the transformation data the of control non-normality the logarithmic between Finally, the to comparisons of group. distribution), used Because each multiple test. within was Kolmogorov–Smirnov for comparisons the covariance comparison for using tests of hoc t post analysis student paired-sample Dunnett’s multivariate by one-way followed A differences, variables. categorical mean a for as presented are control. results internal The an as used Shiga, was 2 analysis Snordu6 Inc, Taq as Statistical miRNA Ex Bio calculated The Premix (Takara was Table4. SYBR(r) kit the in expression using illustrated reagent gene performed been RT in relative was liquated Script PCR and (Takara) Real-time were Prime samples II protocol. by manufacturer RNA on synthesized The Based was Japan). nm. (cDNA) 280 DNA and -70 and Complementary 260 at concentration 230, stored The and length manual. Technologies, wave tubes drop user free at (Nano the RNase reading spectrophotometer to ND-1000 USA) drop according Nano DE, Japan) by Wilmington, evaluated Shiga, was RNAs Inc, extracted ice Bio of (Takara on purity digestion retained were I 100 vials DNase from The by groups. -70 extracted placebo at was the frozen placebo RNA and then the Total intervention and the from study 3000g the both subjects at at in 21 centrifugation analyzed study chilled were and of microRNAs before end group, The the treatment microRNA. at active the and regarding the start evaluated from and participants randomized and were 22 tube group participants, fresh min 44 a 1 of to in for Out transferred min vortex-mixed analysis was 45 and MicroRNA layer for mixture and organic heated extraction the The nm was RNA added 532 min. mixture was at 20 the n-butanol measured for and was of rpm tube absorbance ml 20000 centrifuge its 4 at a cooling, centrifugation in After by homogenate followed bath. of water ml boiling 0.5 a to added was (0.6%) Tmto.Tecmaio ewe ruswscridotwt h n-a NV rKruskal- or ANOVA one-way the with out carried was groups between comparison The method. CT ° μ eoeuse. before C ± fsrmsml sn N-lsraet(ingn rn followed Iran) (Cinnagen, reagent RNX-Plus using sample serum of L tnaderrfrcniuu aibe,ada ubr (percentages) numbers as and variables, continuous for error standard 16 . Table1 3 sidctd osaitclysgicn difference significant statistically no indicated, As . ° ,adn apewsmle oeta twice. than more melted was sample no and C, -Ct h ito rmr o pcfi ee has genes specific for primers of list The . 17 nadto,n infiatchanges significant no addition, In . P 0.062). = < 0.05. Posted on Authorea 16 Sep 2020 — The copyright holder is the author/funder. All rights reserved. No reuse without permission. — https://doi.org/10.22541/au.160029792.26609294 — This a preprint and has not been peer reviewed. Data may be preliminary. nsmay u eut nrdcd8m/dyo S upeetto o ek sanwaetfor agent new a as weeks 8 for supplementation AST of day mg/ 8 introduced considered results be our should summary, findings In our and goal indicated. this is achieve demonstrate studies Conclusion to further not pathways. urgent for could inflammatory are requirement we reducing studies the and through and size outcome levels of preliminary sample genetic miR-126 lack of larger plasma a have process further modulating studies. we the on So other and AST with affect miRNAs patients may of circulating diabetes agents duration on antioxidant on study AST supplementation short of AST addition, effect of the effect In assesses potential that the comparing study experiments first with the line onset is in this diabetes However, were 2 type study abundant cells most of present endothelial the predictor from the a release, bodies, from as miR-126 apoptotic results reduced endothelial significantly miR-146a, the hyperglycemia in controls that Furthermore, high miRNAs healthy revealed that show biomarkers. studies with and DM several compared report cells. explore previous addition, patients T a In diabetes in as 2 results. IL-21 miRNAs type obtained and in IL-6 our overexpressed of with is production consistent the in studies inhibited results previous miR-146a with These elevated consistent during whereas, is augmented mediators, which was MDA inflammatory miR-146a by and of conducted IL-6 expression study raised a the in with that rat indicated associated increased extracting we and intervention antioxidant group, mango the literature the placebo with as attenuated to cells and many wine context treating MicroRNAs red in in by of Moreover, from regulation confirmed management up was extracted disease the cytokines studies polyphenols Also, in pro-inflammatory previous of of manner. target in effect dose-dependent expression a therapeutic potential examined in that patients novel the was MicroRNAs showed T2D stated plasma a MicroRNAs a studies al, the as circulating of other et in on consider consequence the Morales marker antioxidants to the from inflammatory some suggested be results an of and not might the with effect was behavior regard, associated modulatory patients expression this was AST-supplemented the miR-146a In expression in on T2D. relative miR-126 AST the miR-146a of of of level release effect component expression moderated a pro-inflammatory specific high miR-146-a. with the This of associated However, level expression MDA. significant. expression miR-146a eight the and of levels. reduced for IL-6 inhibition IL-6 significantly supplementation and that of supplementation MDA displayed AST AST of results mg/day the improvement our of 8 also Moreover, mg and of 8 miR-126a, effect that and observed the miR-146a We determinate of expression to relative order the in on weeks conducted and was miR-126 study of This in changes shown expression was intervention expression The after the 1.185). and to Discussion before factor: comparison group by in placebo up-regulated increased the gene was in (Target gene miR-146-a miR-146 (Target gene circulating decreased reference But, significantly in the was shown -1.233). of miR-126 was of factor: intervention expression by mean after up-regulated the and group, before placebo level (P-value group regarding expression -1/388) However, AST the the change: in that (Fold miR-146 observed group and Table3. we placebo miR-126 of AST, the changes to of expression comparison administration in 8-week decreased the < IL-6 significantly and following level miR-146-a hand, MDA of decrease other could the AST On that indicated groups ( the time significant within were over There comparison values the 2. Table Although in shown is 0.05). intervention after and (paired before IL-6, decreases and MDA of levels plasma IL-6 Mean and MDA miR-126, miR-146a, Circulating .5.Mawieteicesdlvlo h i-2 a eetdbtwsntsaitclysgicn.The significant. statistically not was but detected was miR-126 the of level increased the Meanwhile 0.05). P t ts)i D n L6lvl nATgopcmae ihtepaeogop( group placebo the with compared group AST in levels IL-6 and MDA in -test) < 0.05). 22 oiiecreainwsosre ewe i-4alvl n ocnrto of concentration and levels miR-146a between observed was correlation positive a , 24 . 4 23 n oso miR of loss And . Table3. 8,22 hc tdsrbdserum described it which , - 2 a enproposed been has 126 18 18 Also, . 21 Also . . P 19,20 < . Posted on Authorea 16 Sep 2020 — The copyright holder is the author/funder. All rights reserved. No reuse without permission. — https://doi.org/10.22541/au.160029792.26609294 — This a preprint and has not been peer reviewed. Data may be preliminary. rgnmc n rtoisi elhadDsae oad ytm-ee nesadn fgene–diet of understanding systems-level angiogenesis. a and Towards atherosclerosis Disease: in bioflavonoids and and Health antioxidants in interactions. Dietary Proteomics A. phy- and Azzi by trigenomics M, microRNAs Meydani of Regulation 13. WC. Cho chemoprevention. K, Pakravan cancer for MT, 651. strategy Birgani promising B, A Bakhshinejad tochemicals: S, and blood Babashah earlier function as mellitus. beta-cell suitability 12. diabetes microRNAs 2 of type related and regulators two-diabetes prediabetes of as detecting Evaluation for G. MicroRNAs biomarkers Al-Kafaji H, al. Al-Muhtaresh et for 11. CH, biomarker novel Bang-Berthelsen a Y, (miR-126): Osmai dysfunction. microRNA-126 mellitus. M, circulating diabetes Osmai of 2 10. role type The diagnosed al. et newly sciences. C, and Yang prediabetes G, diagnosed Gao newly screening with Y, patients of Liu plasma 9. in levels microRNA-146a Increased mellitus. al. diabetes et 2 Z, Shan type W, Bao Y, mellitus. Rong diabetes 8. of susceptibility and pathogenesis biology. N the V, in Rottiers miRNAs 7. of genetics. Role human T. of Tanaka Journal N, injury. Hashimoto vascular after thrombosis 6. and restenosis for MicroRNAs C. Indolfi S, research. Rosa De diabetes. islet C, and 2 Gareri mediators type 5. Inflammatory and T. 1 Mandrup-Poulsen type and K, between diet Maedler link Mediterranean J, a between Størling link MY, Donath the in 4. player new review. a a Inflammation: al. mellitus: DB. diabetes Panagiotakos et E, treatment. Koloverou DW, and 3. Bowden prevention KS, for Polonsky Metabolism. prospects PA, and Halban mechanisms mellitus. diabetes of 2. classification and Diagnosis AD. 1):S67-S74. Association not-for- or 1. commercial, public, the in agencies References funding from grant specific any sectors receive profit manuscript. not this did to research related This interest of conflict financial source potential Funding any has authors the Sciences. of Medical None of University Ahvaz interest of of Committee (IRCT2015081623645N1) Trials Ethics Conflict Clinical of Research Registry the Iranian by the in approved protocol was registered which the of part is study This sample larger further However, outcomes. these MiR-146a. Acknowledgment confirm of to expression needed relative are and studies IL-6 size MDA, circulating the decreasing 2012;13(4):239. 2016;118(7):1170-1184. 2014;15(6):10567-10577. 2014;99(6):1983-1992. ibtsmtbls eerhadreviews. and research Diabetes/metabolism 2017:125-142. ¨ a rA.McoNsi eaoimadmtblcdisorders. metabolic and metabolism in MicroRNAs AM. ¨ ar lSone. PloS 2017;62(2):141. urn urto Reports. Nutrition Current 2013;8(9):e73272. ora fmlclrmedicine. molecular of Journal 5 2017;6(3):247-256. 2016;32(4):334-349. β- elfiuei ye2daee:postulated diabetes: 2 type in failure cell h ora fCiia nornlg & Endocrinology Clinical of Journal The urn acrdu targets. drug cancer Current ora fciia medicine. clinical of Journal ibtscare. Diabetes nentoa ora fmolecular of journal International 2003;81(8):455-470. auervesMlclrcell Molecular reviews Nature 2013;36(Supplement 2018;18(7):640- β- 2018;7(2):12. Circulation elfailure: cell Nu- Posted on Authorea 16 Sep 2020 — The copyright holder is the author/funder. All rights reserved. No reuse without permission. — https://doi.org/10.22541/au.160029792.26609294 — This a preprint and has not been peer reviewed. Data may be preliminary. placebo-controlled-clinical-trial and-inflammation-in-patients-with-type-2-diabetes-mellitus-a-randomized-double-blind- astaxanthin-supplementation-on-the-expression-of-mir-146a-and-mir-126-oxidative-stress- tabels.docx file Hosted placebo-controlled-clinical-trial and-inflammation-in-patients-with-type-2-diabetes-mellitus-a-randomized-double-blind- pre- to astaxanthin-supplementation-on-the-expression-of-mir-146a-and-mir-126-oxidative-stress- biomarker potential a figure.docx is miR-126 individuals. Circulating susceptible B. file in Su Hosted mellitus C, diabetes Wang 2 C, type Lv of Q, communications. onset Shang miR-126 L, the endothelial of Li dict loss T, reveals Zhang profiling diabetes. microRNA 24. 2 Plasma type al. in et microRNAs I, Drozdov other S, and state. Kiechl activation A, microglial disea- Zampetaki the prion and during 23. over-expressed response is immune (miR-146a) innate 146a the MicroRNA al. modulates et and in- RL, se Huzarewich of S, Gushue expression R, the Saba 22. microRNA-126. reduce of polyphenolics role potential wine cells: function. myofibroblast Red & CCD-18Co Food S. colon-derived Mertens-Talcott human in G, markers obesity. Noratto flammation in G, biomarkers Angel-Morales inflammation 21. and microRNAs regulating Polyphenols Nutrition. MM. Rogero Trial. Corrˆea TA, Placebo-Controlled 20. Double-Blind, Circulating Randomized, Modulate Journal. Supplements A Medical L.) Crescent sativus Patients; Red (Crocus Atherosclerosis Iranian Saffron in al. et (miR-21) A, Barzegari MicroRNA A, Bayatian SA, Khatir and 19. miR-34a miR-146a, to Circulating relation in parameters. individuals metabolic al. 2019;46(12):1092-1100. normal-glycaemic and and et resistance pre-diabetic DP, insulin patients, Portales-Perez tion, diabetes 2 EE, type Uresti-Rivera in RE, miR-375 mellitus. As- Garcia-Jacobo diabetes MH. 2 Haghighizadeh type 18. nutrition. with M, clinical patients Mohammadshahi of in M, pressure journal blood Zarei Pacific reduces J, Asia and Mohammadiasl metabolism M, glucose improves Zakerkish taxanthin NS, Mashhadi (Crocus its rats. extract in 17. and damage saffron oxidative aqueous mellitus ischemia-reperfusion-induced Sci. of renal diabetes Pharm effect on Protective constituent, Pharm of active A. J its Danaee treatment crocin, T, and the Ziaee L.) HR, in sativus Sadeghnia Carotenoids H, Hosseinzadeh M. 16. Iranshahi in nephropathy G, review. ameliorates mechanistic Karimi by-products A A, shrimp complications: from Roohbakhsh Astaxanthin al. 15. et Z, Kamoun Z, rats. Ghlissi diabetic A, Sila 14. 2019;59:150-157. uoenjunlo nutrition. of journal European vial at available at available 2015;463(1):60-63. 2012;3(7):745-752. 2005;8(3):387-393. https://authorea.com/users/355778/articles/481411-the-effects-of- https://authorea.com/users/355778/articles/481411-the-effects-of- imdcn Pharmacotherapy. & Biomedicine 2018;20(10). 2018;27(2):341. iclto research. Circulation 2015;54(2):301-307. lncladEprmna hraooyadPhysiology. and Pharmacology Experimental and Clinical 6 2010;107(6):810-817. iceia n ipyia research biophysical and Biochemical 2017;91:31-42. lSone. PloS 2012;7(2):e30832. β cl func- -cell